MDP Regulatory Insight

FDA Warning Letter Highlights Fundamental CGMP and Data Integrity Failures

The FDA has issued a Warning Letter to A. Nelson & Co. Ltd. citing significant violations of Current Good Manufacturing Practice (CGMP) requirements under 21 CFR Parts 210 and 211 at a finished pharmaceutical manufacturing facility. At its core, the agency determined that the firm’s manufacturing methods, controls, and quality systems were inadequate, rendering its drug products adulterated under the Federal Food, Drug, and Cosmetic Act.

While Warning Letters often cite technical gaps, this one points to something more foundational. A breakdown of scientific control, quality oversight, and data integrity.

Key Findings

Failure to Perform Required Microbial Testing

The manufacturer released drug products, including homeopathic products intended for children as young as two, without adequate microbial testing.

Cited deficiencies included a failure to test every batch for microbial contamination prior to release, conducting only limited or selective testing, and releasing products without confirming absence of objectionable microorganisms.

Of particular concern, one product batch was detained and refused at the U.S. border due to microbial contamination.

Additionally, the firm extended product expiration dates without supporting stability data and marketed products beyond scientifically justified shelf life.

FDA’s position was clear. Without batch-level testing, there is no scientific assurance of product safety.

Quality Unit Breakdown

The inspection revealed systemic failures in the firm’s Quality Unit (QU), including inadequate oversight of manufacturing quality, improper retention and disposal of CGMP documentation, and discarded analytical records showing unacceptable results.

Perhaps most striking, inspectors found a handwritten sticky note documenting an “out-of-trend” result with no formal investigation.

This is a textbook example of informal decision-making replacing controlled quality processes.

Such practices raise significant questions about whether quality decisions were being made scientifically, or administratively.

Data Integrity Concerns

FDA observed the generation of duplicate records without tracking procedures, disposal of records that should have triggered investigations, and a lack of documented deviation management.

These failures undermine confidence in manufacturing records, analytical data, and release decisions.

FDA emphasized in its warning letter that data integrity must be maintained across the full lifecycle, from creation through archival.

In addition, the firm’s delayed plan to engage an external auditor (not until May 2026) was deemed inadequate given the severity of deficiencies.

API Manufacturing Expectations

The firm also manufactures homeopathic active pharmaceutical ingredients (APIs). FDA reminded the company that ICH Q7 expectations apply to API manufacturing. This reinforces that even niche or homeopathic products must meet globally recognized CGMP standards.

FDA Expectations Moving Forward

The agency requires the firm to perform full microbial and chemical testing of retained samples, a comprehensive quality system remediation plan, a global data integrity investigation, risk assessments evaluating potential patient impact, and a robust CAPA strategy.

FDA also strongly recommended engaging a qualified CGMP consultant to perform a full six-system audit.

Potential Regulatory Consequences

If deficiencies are not promptly addressed, FDA warned that it may withhold approval of future applications, refuse U.S. importation of products, and detain shipments at the border.

MDP Commentary

The Warning Letter reinforces a persistent regulatory truth, that CGMP failures rarely begin with technology. They begin with governance.

The issues of selective testing, undocumented deviations, and discarded records cited in the letter are not merely procedural gaps. They appear to reflect a quality culture that allowed scientific evidence to be optional, stability to be assumed, and data to be managed informally.

The fact that affected products were intended for pediatric use amplifies the risk implications.

FDA’s message is clear. Homeopathic status does not reduce CGMP expectations. In fact, when products are marketed for vulnerable populations, the burden of control becomes even more critical.

From a modern quality systems perspective, this case illustrates the convergence of microbial control, shelf-life justification, quality unit authority, and data integrity governance.

Ultimately, compliance is not achieved through testing alone, but through disciplined decision-making grounded in documented science.